N/A N=18 Proton Therapy for Lymph Nodes in Breast Cancer
Breast Cancer
Primary: Volume of Heart Receiving ≥ 5 Gray (Gy)/Cobalt Gray Equivalent (CGE) — 34.7; 2.7 % of heart receiving >= 5 Gray (Gy) — p=0.0078
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=230 INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
AMD · Wet AMD · Age-Related Macular Degeneration
Primary: Number of Lucentis® Injections Up To And Including Week 52 — 2.64; 2.44; 3.73 Injections
Early Phase 1 N=16 Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
Heart Failure, Congestive
Primary: Determine the Effects of Sitagliptin on Myocardial Glucose Uptake Measured by Myocardial PET Scan — 3.4; 4.1 SUV
Phase 3 N=1,316 Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Infant, Newborn, Diseases · Other Preterm Infants · Infant, Small for Gestational Age
Primary: Survival Without Bronchopulmonary Dysplasia (BPD) — 346; 320 Participants
N/A N=438 Evaluation of VA's Traumatic Brain Injury (TBI) Clinical Reminder and Comprehensive TBI Evaluation (CTBIE)
Traumatic Brain Injury
Primary: Diagnostic Accuracy of the TBI Clinical Reminder Screen (TCRS) — 71; 79; 74; 85 Percentage of participants
N/A N=18 Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D
Spinal Cord Injury
Primary: Days of Data — 9; 7 days
N/A N=10 Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Hunter Syndrome
Primary: Levels of Total Glycosaminoglycan (GAG) in CSF — 816.750 ng/mL
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
N/A N=3,453 An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
Type 2 Diabetes Mellitus
Primary: Median Duration (in Months) of Initial Dual Therapy — 43.2; 20.2 months
N/A N=15 Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers
Tobacco Abuse Smoke
Primary: Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo — 40.9; 0.0 % change
N/A N=408 Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry
Heart Failure
Primary: All-Cause Mortality — 11; 12 participants — p=0.370
Phase 1 N=16 MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Breast Neoplasms
Primary: Incidence of Treatment-emergent AE's — 16 participants
Phase 3 N=905 Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
Chronic Low Back Pain
Primary: Mean Pain Intensity for "Average Pain Over the Last 24 Hours" Score — 3.7; 4.2 units on a scale
Phase 4 N=450 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Schizophrenia
Primary: Time to First Treatment Failure — 416; 226 Days
Phase 3 N=922 Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
Chronic Nonmalignant and Nonneuropathic Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety — 80; 6; 586; 0 participants